BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33012095)

  • 21. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
    Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
    N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vemurafenib and cobimetinib in BRAF-mutated melanoma.
    Rahman A
    Lancet Oncol; 2014 Nov; 15(12):e535. PubMed ID: 25602110
    [No Abstract]   [Full Text] [Related]  

  • 23. Cobimetinib.
    Signorelli J; Shah Gandhi A
    Ann Pharmacother; 2017 Feb; 51(2):146-153. PubMed ID: 27701080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in
    Ribas A; Daud A; Pavlick AC; Gonzalez R; Lewis KD; Hamid O; Gajewski TF; Puzanov I; Wongchenko M; Rooney I; Hsu JJ; Yan Y; Park E; McArthur GA
    Clin Cancer Res; 2020 Jan; 26(1):46-53. PubMed ID: 31732523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunosuppressant-induced acneiform eruption of the breast.
    Mackesy MM; Selhorst C; Raza S
    Breast J; 2014; 20(6):650-2. PubMed ID: 25229395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene Expression Profiling in
    Wongchenko MJ; McArthur GA; Dréno B; Larkin J; Ascierto PA; Sosman J; Andries L; Kockx M; Hurst SD; Caro I; Rooney I; Hegde PS; Molinero L; Yue H; Chang I; Amler L; Yan Y; Ribas A
    Clin Cancer Res; 2017 Sep; 23(17):5238-5245. PubMed ID: 28536307
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAF
    Lewis K; Hauschild A; Larkin J; Ribas A; Flaherty KT; McArthur GA; Dréno B; McKenna E; Zhu Q; Mun Y; Ascierto PA
    Eur J Cancer; 2019 Jul; 116():45-55. PubMed ID: 31173962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Vemurafenib-induced radiation recall dermatitis].
    Greliak A; Le Guern A; Bataille M; Lebas D; Wiart T; Modiano P
    Ann Dermatol Venereol; 2019 May; 146(5):382-384. PubMed ID: 30981540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM.
    Lewis KD; Larkin J; Ribas A; Flaherty KT; McArthur GA; Ascierto PA; Dréno B; Yan Y; Wongchenko M; McKenna E; Zhu Q; Mun Y; Hauschild A
    Br J Cancer; 2019 Oct; 121(7):522-528. PubMed ID: 31417188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials.
    Hopkins AM; Rathod AD; Rowland A; Kichenadasse G; Sorich MJ
    BMC Cancer; 2020 Feb; 20(1):157. PubMed ID: 32103736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
    Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
    JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MEK Retinopathy. Clinical case reports.
    Rocha Cabrera P; Quijada Fumero E; Losada Castillo MJ; Abreu Reyes JA; Lorenzo Morales J
    Arch Soc Esp Oftalmol (Engl Ed); 2018 Jan; 93(1):42-46. PubMed ID: 28506716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New primary melanoma in a patient under triple therapy with vemurafenib, cobimetinib, and atezolizumab for metastatic melanoma.
    Diamantopoulos PT; Lakiotaki E; Kyriakakis G; Gogas H
    Melanoma Res; 2020 Apr; 30(2):206-208. PubMed ID: 31157737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hidradenitis suppurativa, eruptive melanocytic nevi, and keratosis pilaris-like eruption in a patient treated with vemurafenib.
    Ma L; Dominguez AR; Collins GR; Kia KF; Cockerell CJ
    Arch Dermatol; 2012 Dec; 148(12):1428-9. PubMed ID: 23247496
    [No Abstract]   [Full Text] [Related]  

  • 35. RASopathic comedone-like or cystic lesions induced by vemurafenib: a model of skin lesions similar but not identical to those induced by dioxins MADISH.
    Kaya G; Saxer-Sekulic N; Kaya A; Sorg O; Boespflug A; Thomas L; Saurat JH
    J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1368-1372. PubMed ID: 29575357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A status report on drug-associated acne and acneiform eruptions.
    Momin SB; Peterson A; Del Rosso JQ
    J Drugs Dermatol; 2010 Jun; 9(6):627-36. PubMed ID: 20645524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two cases of pneumonitis induced by targeted therapy.
    Lafabregue E; Arnault JP; Auquier M; Magois E; Chaby G; Lok C
    Melanoma Res; 2019 Aug; 29(4):441-443. PubMed ID: 31260421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aripiprazole-induced acneiform eruption.
    Mishra B; Praharaj SK; Prakash R; Sinha VK
    Gen Hosp Psychiatry; 2008; 30(5):479-81. PubMed ID: 18774434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DRESS syndrome due to vemurafenib treatment: switching BRAF inhibitor to solve a big problem.
    Ros J; Muñoz-Couselo E
    BMJ Case Rep; 2018 Sep; 2018():. PubMed ID: 30275021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acneiform eruption caused by amineptine. A case report and review of the literature.
    De Gálvez Aranda MV; Sánchez PS; Alonso Corral MJ; Bosch García RJ; Gallardo MA; Herrera Ceballos E
    J Eur Acad Dermatol Venereol; 2001 Jul; 15(4):337-9. PubMed ID: 11730047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.